Abstract
Nuclear factor-kappaB (NF-κB) is a signal-activated transcription factor complex with two functional subunits and controls the expression of >600 genes in the human genome. This protein complex was initially identified and described as a nuclear protein complex uniquely present in cells that transcribe immunoglobulin light chain genes. Hence, its pro-oncogenic functions were studied only in the context of hematologic malignancies. However, subsequent studies showed the presence of this complex in almost all cell types. Early studies of this complex suggested only pro-oncogenic role, which triggered massive interest in both academia and industry in developing drugs targeting this transcription factor complex. Because NF-κB activation requires multiple enzymatic steps, it is one of the few transcriptional regulators that are therapeutically targetable. Recent studies, however, have revealed both tumor suppressor and pro-oncogenic functions depending on the cellular context, stage of the disease, and concomitant genomic aberration in cancer cells. During initiation stage of tumorigenesis, NF-κB activates senescence program and prevents damaged cells from proliferating. During later stage, it promotes tumorigenesis by activating anti-apoptotic, pro-inflammatory, pro-metastatic, and tumor-immune suppressive machineries. Amplifications, mutations, and rare deletions in various components of NF-κB pathway are observed in multiple cancer types, and IKKε among them is a proven oncogene and is amplified in >30% of breast cancers. These complexities in NF-κB activities need to be taken into consideration while designing clinical trials with drugs with NF-κB inhibitory activity. Although specific inhibitors of NF-κB are yet to enter oncology clinic, NF-κB is one of the targets of several FDA-approved drugs including bortezomib used for treating multiple myeloma.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- COX2:
-
Cyclooxygenase 2
- CSN5:
-
COP9 signalosome 5
- CXCL:
-
Chemokine (C-X-C) ligand
- CXCR:
-
Chemokine (C-X-C) receptor
- EGFR:
-
Epidermal growth factor receptor
- ERBB2:
-
ERB-B2 receptor tyrosine kinase 2
- FAS:
-
Fas cell death receptor
- FASL:
-
FAS ligand
- IAP:
-
Inhibitor of apoptosis
- IKK:
-
IκB kinase
- IL:
-
Interleukin
- IκB:
-
Inhibitor of kappaB
- MLL:
-
Mixed lineage leukemia
- MMP:
-
Matrix metalloproteinase
- MyoD:
-
Myogenic differentiation 1
- NF-κB:
-
Nuclear factor-kappaB
- PD-L1:
-
Programmed death ligand 1
- PIK3CA:
-
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
- SASP:
-
Senescence-associated secretory phenotype
- TNF:
-
Tumor necrosis factor
- ZEB:
-
Zinc finger E-box-binding homeobox
References
Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26(3):203–34.
Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301–10.
Salminen A, Kauppinen A, Kaarniranta K. Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal. 2012;24(4):835–45.
Lesina M, Wormann SM, Morton J, Diakopoulos KN, Korneeva O, Wimmer M, et al. RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis. J Clin Invest. 2016;126(8):2919–32.
Klein U, Ghosh S. The two faces of NF-kappaB signaling in cancer development and therapy. Cancer Cell. 2011;20(5):556–8.
Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006;13(5):759–72.
Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. 2009;462(7269):104–7.
Kuo HP, Wang Z, Lee DF, Iwasaki M, Duque-Afonso J, Wong SH, et al. Epigenetic roles of MLL oncoproteins are dependent on NF-kappaB. Cancer Cell. 2013;24(4):423–37.
Bakkar N, Guttridge DC. NF-kappaB signaling: a tale of two pathways in skeletal myogenesis. Physiol Rev. 2010;90(2):495–511.
Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925–39.
DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012;246(1):379–400.
Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012;12(2):121–32.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nakshatri, H. (2019). NF-κB Signaling Pathways in Carcinogenesis. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_27
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_27
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)